 |
| Global Consensus on Metabolic and bariatric Surgery Key Finding and Recommendations |
Experts from 32 countries recently conducted an international study involving 78 specialists in metabolic and bariatric surgery (MBS). The study provided valuable insights into the effectiveness of MBS as a treatment option for obesity and Type 2 Diabetes Mellitus (T2DM). Considered a significant consensus in the field, the study indicated that MBS is a cost-effective treatment for patients with Class II obesity, regardless of the presence or absence of obesity-related medical conditions.
Furthermore, the study
suggested that MBS should be considered for patients with Class I obesity who
It also highlighted MBS as a potential treatment for patients with T2DM and a BMI of 30
kg/m or higher.
The experts
discussed various MBS procedures, including intra-gastric balloon (IGB),
bypass (OAGB). They explored the efficacy of these procedures for different
patient categories, identifying areas of agreement and disagreement among
specialists.
Both the American the study's findings and issued.
Research also
non-alcoholic fatty liver disease, with ongoing studies examining the potential
influence of low-density lipoprotein on this outcome.
In a separate study
conducted on serving patients in the Indian Armed Forces, bariatric surgery
demonstrated positive effects on body mass index (BMI), co-morbidities, and
employability. Out of 35 patients who underwent surgery over a ten-year period,
80% were able to return to active duties, showing significant improvements in
diabetes mellitus control and obstructive sleep apnea.
Additionally, a
single blinded randomized controlled trial compared the outcomes of
laparoscopic sleeve gastrectomy (LSG) and one anastomosis gastric bypass (OAGB)
over a 5-year follow-up period. OAGB showed superior weight loss effectiveness
and durability, with significantly less de novo gastroesophageal reflux disease
(GERD), albeit with a higher incidence of bile reflux.